Cadrenal Therapeutics reports Q4 results, updates program

Cadrenal Therapeutics has announced its fourth-quarter 2025 financial results and provided an update on its CAD-1005 program for HIT. Encouraging Phase 2 data and recent FDA feedback support the continued advancement of CAD-1005 as a near-term development priority. The company is focusing on its 12-LOX inhibitor program, aiming to bring promising therapies to market. This update highlights Cadrenal's progress in its drug development pipeline and its commitment to addressing unmet medical needs.